[ad_1]
The Butantan Institute admitted that it used American technology to obtain the viral vector ButanVac. The covid-19 vaccine was announced as “100% Brazilian” hours before by Governor João Doria (PSDB-SP) this Friday (Mar 26, 2021).
Doria stated at a press conference this morning that the immunizer “It is the 1st 100% national vaccine, fully developed and produced in Brazil by the Butantan Institute”. Hours later, the newspaper Folha de S. Paulo published a report challenging the information.
ButanVac uses the Newcastle disease variant as a vector. The technology to produce vaccines with this specific virus is from the Mount Sinai Institute, in the United States. The event was omitted from the press conference held by Butantan and the São Paulo government.
Only after the publication of the news of the leaf, Butantan admitted to having “Association and license to use and exploit part of the technology that was developed by the Icahn School of Medicine at Mount Sinai Hospital in New York, to obtain the virus.”
The institute argues: “You do not have a vaccine only with this technology to obtain the virus.” He states that there are other stages in the development of the immunizer and goes on to say that “ButanVac is Brazilian.”
Read the full note:
“The Butantan Institute clarifies that the production of ButanVac, the first Brazilian vaccine against the new coronavirus, will be 100% national, as announced on the morning of this Friday, March 26, at a press conference.
To do this, he signed a partnership and has a license to use and explore part of the technology, which was developed by the Icahn School of Medicine at Mount Sinai Hospital in New York, to obtain the virus. The use of this technology is royalty free and can be carried out by any research institution anywhere in the world. This was adopted for this technology in order to accelerate the development of vaccines against the coronavirus.
However, a vaccine with only this technology is not available to obtain the virus. At that time, the development of the vaccine begins entirely with the Butantan technology. Among the steps carried out entirely by techniques developed by the São Paulo Institute, are the multiplication of the virus, culture conditions, ingredients, adaptation to eggs, conservation, purification, inactivation of the virus, dose escalation, clinical and regulatory studies, in addition to record.
It is important to highlight that ButanVac is and will be developed entirely in the country, and the international consortium plays a very important role in the conception of the technology and in the technical support for the development of immunobiology, something fundamental for safety and efficacy. vaccine.
In Brazil, the developer of the vaccine is the Butantan Institute. The vaccine, therefore, is Brazilian and Brazilian. The article published by Folha de S. Paulo includes an unofficial statement from a researcher from the North American institution. The institution did not authorize the disclosure of his name in official communications from Butantan about the new vaccine.
Joint communications will be made by members of the consortium at the appropriate time, including the institution cited by Folha.
The vaccine belongs to the consortium. ButanVac is Brazilian ”.
What Mount Sinai Says
TO leaf, Peter Palese, stated that there is “An agreement with the Butantan Institute to enter into clinical trials in Brazil”. He also claimed that Sinai conducted preclinical trials, that is, tests on animals.
The North American institute also began to carry out tests in humans: “We have successfully conducted experiments with our Newcastle disease virus-based vaccine. [NVD, um tipo de gripe aviária]. Meanwhile, we have started phase 1 testing in Vietnam and Thailand with our new generation (improved) of the covid vaccine. We are conducting a phase 1 test here at Mount Sinai”Palese said in an email.
The “enhanced” generation consists of a version of the vaccine that uses parts of the Newcastle disease virus, not the entire virus.
Palese adds that Mount Sinai unfolds “Vaccines for covid-19 variants based on the South African and Brazilian versions for the Butantan Institute”.
The Newcastle disease covid-19 vaccine was the subject of a study published in December 2020 by Mount Sinai researchers.
“100% national”
ButanVac’s main differential for vaccines bought by the Brazilian government are supplies. While the other immunizers depend, at least for now, on imported raw material, ButanVac can be produced entirely in Brazil.
Watch João Doria’s speech at ButanVac (2min50s):
keep reading
[ad_2]
